Regulatory issues in cellular therapies.
Cellular and gene therapies offer considerable promise as new treatment modalities. The Food and Drug Administration has been developing strategies to regulate these rapidly evolving fields in a manner that sustains progress and also ensures minimization of potential risks. The death of a patient on a gene therapy study highlighted a number of potential problems that have galvanized the agency to examine their strategy and to review current regulations for gene therapy. Meanwhile, a unified regulatory approach is emerging for cell-based therapies. This stratifies the level of regulation based upon the potential risk to the donor of the cells and the recipient. In this article the history and status of regulation of cellular therapy is briefly reviewed.
Gee
Adrian P
AP
Center for Cell and Gene Therapy, Baylor College of Medicine Houston, Texas 77030, USA. apgee@txccc.org
D064987:Cell- and Tissue-Based Therapy / Q000009:adverse effects / Q000592:standards*; D004282:Documentation; D005161:Facility Regulation and Control / Q000331:legislation & jurisprudence; D015316:Genetic Therapy / Q000009:adverse effects / Q000592:standards*; D006801:Humans; D011787:Quality of Health Care / Q000331:legislation & jurisprudence; D012306:Risk; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence*